Skip to main content

ImmunityBio, Inc.

For the period ended Dec 31, 2025. Filed Feb 23, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 23, 2026

IBRX$8.64+7.8%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, as amended, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.

IMMUNITYBIO, INC.
Registrant
Date: February 23, 2026By:/s/ Richard Adcock
Richard Adcock
Chief Executive Officer
(Principal Executive Officer)
Date: February 23, 2026By:/s/ David C. Sachs
David C. Sachs
Chief Financial Officer
(Principal Financial Officer)
Date: February 23, 2026By:/s/ Regan J. Lauer
Regan J. Lauer
Chief Accounting Officer
(Principal Accounting Officer)

POWER OF ATTORNEY

Each person whose signature appears below constitutes and appoints Richard Adcock, David C. Sachs and Philip LoScalzo, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes, may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Patrick Soon-ShiongGlobal Chief Scientific and Medical Officer, and Executive Chairman of the Board of DirectorsFebruary 23, 2026
Patrick Soon-Shiong
/s/ Richard AdcockChief Executive Officer, President and Director(Principal Executive Officer)February 23, 2026
Richard Adcock
/s/ David C. SachsChief Financial Officer(Principal Financial Officer)February 23, 2026
David C. Sachs
/s/ Regan J. LauerChief Accounting Officer(Principal Accounting Officer)February 23, 2026
Regan J. Lauer
/s/ Barry J. SimonChief Corporate Affairs Officer and DirectorFebruary 23, 2026
Barry J. Simon
/s/ Michael BlaszykDirectorFebruary 23, 2026
Michael D. Blaszyk
/s/ Wesley ClarkDirectorFebruary 23, 2026
Wesley Clark
/s/ Cheryl L. CohenLead Independent DirectorFebruary 23, 2026
Cheryl L. Cohen
/s/ Linda MaxwellDirectorFebruary 23, 2026
Linda Maxwell
/s/ Christobel SeleckyDirectorFebruary 23, 2026
Christobel Selecky
/s/ Bruce WendelDirectorFebruary 23, 2026
Bruce Wendel
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.